We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

58 hedge funds and large institutions have $110M invested in Xenon Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

1.22% less ownership

Funds ownership: 70.37% → 69.15% (-1.2%)

2% less funds holding

Funds holding: 59 → 58 (-1)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

53% less capital invested

Capital invested by funds: $234M → $110M (-$124M)

Holders
58
Holders Change
-1
Holders Change %
-1.69%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
12
Increased
23
Reduced
6
Closed
12
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$5.54M
2
ACM
Aquilo Capital Management
California
+$3.19M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.89M
4
BlackRock
BlackRock
New York
+$2.52M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.61M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$11.8M
2
OM
Opaleye Management
Massachusetts
-$7.01M
3
FCMI
Foresite Capital Management IV
California
-$5.09M
4
JG
Jefferies Group
New York
-$4.3M
5
BC
Boxer Capital
California
-$3.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
51
Russell Investments Group
United Kingdom
$27K +$37.4K +4,212 New
Barclays
52
Barclays
United Kingdom
$24K +$33.1K +3,727 New
TI
53
TT International
United Kingdom
$17K – – –
Bank of America
54
Bank of America
North Carolina
$8K +$11.8K +1,329 New
Citigroup
55
Citigroup
New York
$4K – – –
Wells Fargo
56
Wells Fargo
California
$2K – – –
TRCT
57
Tower Research Capital (TRC)
New York
$2K +$1.46K +164 +164%
UBS Group
58
UBS Group
Switzerland
$1K -$6.26K -705 -83%
BC
59
Broadfin Capital
New York
– -$11.8M -895,553 Closed
OM
60
Opaleye Management
Massachusetts
– -$7.01M -465,200 Closed
FCMI
61
Foresite Capital Management IV
California
– -$5.09M -385,714 Closed
JG
62
Jefferies Group
New York
– -$4.3M -325,630 Closed
BC
63
Boxer Capital
California
– -$3.96M -300,000 Closed
AG
64
Artal Group
Luxembourg
– -$3.3M -250,000 Closed
SCM
65
Stonepine Capital Management
Oregon
– -$1.32M -100,000 Closed
JC
66
JBF Capital
Colorado
– -$528K -40,000 Closed
PP
67
PDT Partners
New York
– -$212K -16,074 Closed
Walleye Trading
68
Walleye Trading
New York
– -$151K -11,470 Closed
AAMU
69
Amundi Asset Management US
Massachusetts
– -$148K -11,200 Closed
DWA
70
Dorsey Wright & Associates
California
– -$16K -1,184 Closed
1 2
3

XENE Hedge Fund Activity: Q4 2018 in Review

58 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2018, worth a combined $110M — down 53% from $234M a quarter earlier.

Fund positioning in XENE was balanced in Q4 2018: 12 funds opened new positions, 12 closed out, 23 added to existing stakes and 6 trimmed.

The largest buyer was BVF Inc, adding an estimated $5.54M. The largest seller was Broadfin Capital, exiting entirely with an estimated $11.8M sold.

  • 58 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2018, down from 59 in Q3 2018.
  • Funds reported $110M of Xenon Pharmaceuticals stock for Q4 2018, down 53% quarter-over-quarter.
  • 12 funds opened new Xenon Pharmaceuticals positions in Q4 2018 and 12 closed out, a net change of 0 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2018 was BVF Inc, an estimated $5.54M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2018 was Broadfin Capital, an estimated $11.8M sold.

Based on aggregated 13F filings for Q4 2018.